Clinical · Molecular biology
The Pan-tumor Landscape, Allelic Status, and Genomic Complexity of SMARCA4 Alterations
This large-scale pan-cancer study of nearly 69,000 tumor-normal pairs profiled by MSK-IMPACT characterizes the biological and clinical implications of SMARCA4 alterations across functional mutation classes and allelic configurations. SMARCA4 alterations were most frequently observed in thymic epithelial tumors (10.7%), non-small cell lung cancer (7.1%), bladder cancer (5.6%), and cervical cancer (5%). Distinct profiles of genomic complexity, co-mutations, and mutational signatures were associated with specific allelic states (monoallelic vs. biallelic) and mutation classes (class 1 vs. class 2). Preliminary data from a phase I trial of the BRM degrader PRT3789 revealed clinical benefit, including one complete response, among patients harboring monoallelic class 2 SMARCA4 alterations with preserved BRG1 expression.